human growth hormone

Summary

Summary: A 191-amino acid polypeptide hormone secreted by the human adenohypophysis (PITUITARY GLAND, ANTERIOR), also known as GH or somatotropin. Synthetic growth hormone, termed somatropin, has replaced the natural form in therapeutic usage such as treatment of dwarfism in children with growth hormone deficiency.

Top Publications

  1. ncbi Compliance and persistence in pediatric and adult patients receiving growth hormone therapy
    Ron G Rosenfeld
    The Lucile Packard Foundation, Children s Health, Palo Alto, California 94301, USA
    Endocr Pract 14:143-54. 2008
  2. ncbi A consensus on criteria for cure of acromegaly
    A Giustina
    Department of Medical and Surgical Sciences, University of Brescia, Endocrine Service, Montichiari Hospital, Via Ciotti 154, 25018 Montichiari, Italy
    J Clin Endocrinol Metab 95:3141-8. 2010
  3. ncbi The endocrinology of aging
    S W Lamberts
    Department of Medicine, Erasmus University, Rotterdam, Netherlands
    Science 278:419-24. 1997
  4. ncbi Systemic complications of acromegaly: epidemiology, pathogenesis, and management
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, 80131 Naples, Italy
    Endocr Rev 25:102-52. 2004
  5. ncbi Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, J
    Ken K Y Ho
    Pituitary Research Unit, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
    Eur J Endocrinol 157:695-700. 2007
  6. ncbi SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile
    C Bruns
    Novartis Pharma AG, Research Transplantation, WSJ 386, CH 4002 Basel, Switzerland
    Eur J Endocrinol 146:707-16. 2002
  7. ncbi Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects
    Niels Møller
    Medical Department M, Aarhus University Hospital, Aarhus Sygehus, DK, Aarhus, Denmak
    Endocr Rev 30:152-77. 2009
  8. pmc A novel long-acting human growth hormone fusion protein (VRS-317): enhanced in vivo potency and half-life
    Jeffrey L Cleland
    Versartis, Inc, Redwood City, California, USA
    J Pharm Sci 101:2744-54. 2012
  9. ncbi Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial
    Andrew R Hoffman
    Veterans Affairs Palo Alto Health Care System and Stanford University, Palo Alto, California 94304, USA
    J Clin Endocrinol Metab 89:2048-56. 2004
  10. ncbi Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children
    Pinchas Cohen
    Pediatric Endocrinology, Mattel Children s Hospital at University of California, Los Angeles, 10833 Le Conte Avenue, MDCC 22 315, Los Angeles, California 90095, USA
    J Clin Endocrinol Metab 95:2089-98. 2010

Detail Information

Publications390 found, 100 shown here

  1. ncbi Compliance and persistence in pediatric and adult patients receiving growth hormone therapy
    Ron G Rosenfeld
    The Lucile Packard Foundation, Children s Health, Palo Alto, California 94301, USA
    Endocr Pract 14:143-54. 2008
    ..To identify key factors that influence compliance and persistence in patients receiving growth hormone (GH) therapy and to promote the development of interventions to support continuous GH use...
  2. ncbi A consensus on criteria for cure of acromegaly
    A Giustina
    Department of Medical and Surgical Sciences, University of Brescia, Endocrine Service, Montichiari Hospital, Via Ciotti 154, 25018 Montichiari, Italy
    J Clin Endocrinol Metab 95:3141-8. 2010
    ..The Acromegaly Consensus Group met in April 2009 to revisit the guidelines on criteria for cure as defined in 2000...
  3. ncbi The endocrinology of aging
    S W Lamberts
    Department of Medicine, Erasmus University, Rotterdam, Netherlands
    Science 278:419-24. 1997
    ....
  4. ncbi Systemic complications of acromegaly: epidemiology, pathogenesis, and management
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, 80131 Naples, Italy
    Endocr Rev 25:102-52. 2004
    ..Finally, the most important cause of morbidity and functional disability of the disease is arthropathy, which can be reversed at an initial stage, but not if the disease is left untreated for several years...
  5. ncbi Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, J
    Ken K Y Ho
    Pituitary Research Unit, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
    Eur J Endocrinol 157:695-700. 2007
    ..The GH Research Society held a Consensus Workshop in Sydney, Australia, 2007 to incorporate the important advances in the management of GH deficiency (GHD) in adults, which have taken place since the inaugural 1997 Consensus Workshop...
  6. ncbi SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile
    C Bruns
    Novartis Pharma AG, Research Transplantation, WSJ 386, CH 4002 Basel, Switzerland
    Eur J Endocrinol 146:707-16. 2002
    ....
  7. ncbi Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects
    Niels Møller
    Medical Department M, Aarhus University Hospital, Aarhus Sygehus, DK, Aarhus, Denmak
    Endocr Rev 30:152-77. 2009
    ..Conversely, despite increased LBM and decreased fat mass, patients with acromegaly are consistently insulin resistant and become more sensitive after appropriate treatment...
  8. pmc A novel long-acting human growth hormone fusion protein (VRS-317): enhanced in vivo potency and half-life
    Jeffrey L Cleland
    Versartis, Inc, Redwood City, California, USA
    J Pharm Sci 101:2744-54. 2012
    A novel recombinant human growth hormone (rhGH) fusion protein (VRS-317) was designed to minimize receptor-mediated clearance through a reduction in receptor binding without mutations to rhGH by genetically fusing with XTEN amino acid ..
  9. ncbi Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial
    Andrew R Hoffman
    Veterans Affairs Palo Alto Health Care System and Stanford University, Palo Alto, California 94304, USA
    J Clin Endocrinol Metab 89:2048-56. 2004
    ..GH treatment was generally well tolerated. Subjects with AGHD should receive individualized GH therapy to maintain IGF-I between the mean value and +2 SD and improve body composition and cardiovascular risk factors...
  10. ncbi Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children
    Pinchas Cohen
    Pediatric Endocrinology, Mattel Children s Hospital at University of California, Los Angeles, 10833 Le Conte Avenue, MDCC 22 315, Los Angeles, California 90095, USA
    J Clin Endocrinol Metab 95:2089-98. 2010
    ..We recently showed that, in IGF-based GH therapy, the IGF-I target chosen affects GH dose requirements, and higher IGF-I targets are associated with more robust growth parameters...
  11. ncbi Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD)
    Ferenc Peter
    Buda Children s Hospital, 1023 Budapest, Hungary
    J Clin Endocrinol Metab 97:400-7. 2012
    ..A GH regimen with fewer injections may offer patients and caregivers a less arduous option. LB03002 is a novel sustained-release GH formulation for once-weekly dosing...
  12. ncbi Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study
    Jean Claude Carel
    Department of Pediatric Endocrinology and Diabetology, Institut National de la Santé et de la Recherche Mdicale CIE5, Paris, France
    J Clin Endocrinol Metab 97:416-25. 2012
    ..Little is known about the long-term health of subjects treated with GH in childhood, and Safety and Appropriateness of Growth hormone treatments in Europe (SAGhE) is a study addressing this question...
  13. pmc Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone
    David J Irwin
    Center for Neurodegenerative Disease Research and Institute on Aging, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    JAMA Neurol 70:462-8. 2013
    ..There are limited data on the potential human-to-human transmission of NDAPs associated with Alzheimer disease (AD) and other non-PrPsc ND...
  14. ncbi Growth hormone insensitivity associated with a STAT5b mutation
    Eric M Kofoed
    Department of Pediatrics, Oregon Health and Science University, Portland, USA
    N Engl J Med 349:1139-47. 2003
  15. ncbi Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline
    Mark E Molitch
    Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    J Clin Endocrinol Metab 96:1587-609. 2011
    ..The aim was to update The Endocrine Society Clinical Practice Guideline on Evaluation and Treatment of Adult Growth Hormone Deficiency (GHD) previously published in 2006...
  16. ncbi The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'
    Panagiotis Nomikos
    Department of Neurosurgery, University of Erlangen Nurnberg, Erlangen, Germany
    Eur J Endocrinol 152:379-87. 2005
    ..The aim of this study was to illustrate the present role of transsphenoidal surgery as primary therapy in GH-secreting adenomas, and to compare the results concerning control of disease with previous series using older criteria of cure...
  17. ncbi Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study
    Lars Savendahl
    Division of Pediatric Endocrinology, Karolinska University Hospital Q2 08, SE 171 76 Stockholm, Sweden
    J Clin Endocrinol Metab 97:E213-7. 2012
    ..Recently released data from the French part of the European Union Safety and Appropriateness of GH treatments in Europe (EU SAGhE) study have raised concerns on the long-term safety of GH treatment...
  18. ncbi Final height in short children born small for gestational age treated with growth hormone
    Jovanna Dahlgren
    Goteborg Pediatric Growth Research Center, Institute for the Health of Women and Children, The Sahlgrenska Academy at Goteborg University, 416 85 Goteborg, Sweden
    Pediatr Res 57:216-22. 2005
    ..The younger, shorter, and lighter the child at the start of GH treatment, the better the response. Moreover, most of these SGA individuals treated with GH reach their target height...
  19. pmc CREB-independent regulation by CBP is a novel mechanism of human growth hormone gene expression
    L E Cohen
    Division of Endocrinology, Children s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Clin Invest 104:1123-30. 1999
    ..We determined that CBP interacts with Pit-1 and is a cofactor for Pit-1-dependent activation of the human GH promoter. This pathway appears to be independent of CREB, with CPB being the likely target of phosphorylation by PKA...
  20. ncbi Clinical review: Is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or time to consider glucagon testing for adult GH deficiency?
    Kevin C J Yuen
    Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239 3098, USA
    J Clin Endocrinol Metab 94:2702-7. 2009
    ..In this article, we review the existing published data and consensus guidelines and provide recommendations for alternative stimulation tests to the GHRH-ARG test...
  21. ncbi Effects of once-weekly sustained-release growth hormone: a double-blind, placebo-controlled study in adult growth hormone deficiency
    Beverly M K Biller
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Clin Endocrinol Metab 96:1718-26. 2011
    ..LB03002 is a long-acting GH that is administered once a week by s.c. injection...
  22. ncbi Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH
    Philippe Touraine
    Department of Endocrinology and Reproductive Medicine, GH Pitié Salpétrière, Centre de Référence des Maladies Endocriniennes Rares de la Croissance, Universite Paris VI Pierre et Marie Curie, 47 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Eur J Endocrinol 161:533-40. 2009
    ..c. injections. This study was designed to assess its efficacy and safety, in adult GHD subjects...
  23. ncbi Tumor expression of human growth hormone and human prolactin predict a worse survival outcome in patients with mammary or endometrial carcinoma
    Zheng Sheng Wu
    Hefei National Laboratory for Physical Sciences at Microscale, University of Science and Technology of China, Hefei, Anhui 230027, People s Republic of China
    J Clin Endocrinol Metab 96:E1619-29. 2011
    ..However, especially for hGH, the prognostic relevance of tumor expression of these hormones is not well defined...
  24. ncbi A defined locus control region determinant links chromatin domain acetylation with long-range gene activation
    Yugong Ho
    Department of Genetics, University of Pennsylvania, Philadelphia, PA 19104, USA
    Mol Cell 9:291-302. 2002
    ..It is unclear how such long-range control is mediated. Here we show that a single determinant of the human growth hormone locus control region (hGH LCR) located 14...
  25. ncbi Overall and cause-specific mortality in GH-deficient adults on GH replacement
    Rolf C Gaillard
    Department of Endocrinology, Diabetology and Metabolism, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Eur J Endocrinol 166:1069-77. 2012
    ..The purpose of this study was to evaluate mortality and associated factors within a large GH-replaced population of hypopituitary patients...
  26. ncbi Systematic review: the safety and efficacy of growth hormone in the healthy elderly
    Hau Liu
    Stanford University, Stanford, California 94305 6019, USA
    Ann Intern Med 146:104-15. 2007
    b>Human growth hormone (GH) is widely used as an antiaging therapy, although its use for this purpose has not been approved by the U.S. Food and Drug Administration and its distribution as an antiaging agent is illegal in the United States.
  27. ncbi Pharmacokinetics and pharmacodynamic effects of an oral ghrelin agonist in healthy subjects
    Franziska Piccoli
    Clinical Research Center, Department of Research, Division of Gastroenterology, University Hospital, CH 4031 Basel, Switzerland
    J Clin Endocrinol Metab 92:1814-20. 2007
    ..An oral formulation of EP01572, a peptidomimetic growth hormone secretagogue, was studied. An oral delivery system would be preferable in many of the possible therapeutic indications of ghrelin agonists such as EP01572...
  28. ncbi Randomized controlled trial to investigate the effects of growth hormone treatment on scoliosis in children with Prader-Willi syndrome
    Roderick F A de Lind van Wijngaarden
    Dutch Growth Research Foundation, Erasmus University Medical Center Sophia Children s Hospital, Rotterdam, The Netherlands
    J Clin Endocrinol Metab 94:1274-80. 2009
    ..Although reports about effects of GH treatment on scoliosis in children with PWS are limited, scoliosis is generally considered a contraindication for GH treatment...
  29. ncbi Detection of growth hormone doping by gene expression profiling of peripheral blood
    Christopher J Mitchell
    Pituitary Research Unit, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst New South Wales 2010, Sydney, Australia
    J Clin Endocrinol Metab 94:4703-9. 2009
    ..GH abuse is a significant problem in many sports, and there is currently no robust test that allows detection of doping beyond a short window after administration...
  30. pmc Characterisation of a functional intronic polymorphism in the human growth hormone (GH1) gene
    David S Millar
    Institute of Medical Genetics, Cardiff University, Heath Park, UK
    Hum Genomics 4:289-301. 2010
    The +1169A allele of the A/T single nucleotide polymorphism (SNP; rs2665802), located within intron 4 of the human growth hormone 1 ( GH1 ) gene, has been associated with reduced levels of circulating GH and insulin-like growth factor 1, ..
  31. ncbi Do all patients with childhood-onset growth hormone deficiency (GHD) and ectopic neurohypophysis have persistent GHD in adulthood?
    Juliane Leger
    Pediatric Endocrinology and Diabetes Unit, Institut National de la Sante et de la Recherche Medicale, Unité 457, Hopital Robert Debre, 75019 Paris, France
    J Clin Endocrinol Metab 90:650-6. 2005
    ....
  32. ncbi Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticles
    Sun Jin Kim
    Biotech Group, LG Life Sciences Co, 104 1, Moonji dong, Yusong gu, Daejeon, 305 380, South Korea
    J Control Release 104:323-35. 2005
    A novel sustained release formulation of recombinant human growth hormone (SR-rhGH) was developed as a once-a-week injection formulation using sodium hyaluronate...
  33. ncbi Beneficial effects of growth hormone treatment on cognition in children with Prader-Willi syndrome: a randomized controlled trial and longitudinal study
    Elbrich P C Siemensma
    Dutch Growth Research Foundation Erasmus MC Rotterdam, Westzeedijk 106, 3016 AH Rotterdam, The Netherlands
    J Clin Endocrinol Metab 97:2307-14. 2012
    ..Knowledge about the effects of GH treatment on cognitive functioning in children with Prader-Willi syndrome (PWS) is limited...
  34. ncbi Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone
    Aart Jan van der Lely
    Department of Internal Medicine, Erasmus University MC, 40 Dr Molewaterplein, 3015 GD Rotterdam, The Netherlands
    Eur J Endocrinol 164:325-33. 2011
    ..To evaluate the efficacy and safety of coadministered lanreotide Autogel (LA; 120  mg/month) and pegvisomant (40-120  mg/week) in acromegaly...
  35. ncbi Elevated insulin-like growth factor-I values in children with Prader-Willi syndrome compared with growth hormone (GH) deficiency children over two years of GH treatment
    Eva Feigerlová
    Department of Endocrinology, Bone Diseases, Genetics, and Gynaecology, Centre de Référence du Syndrome de Prader Willi, Children s Hospital, Toulouse, France
    J Clin Endocrinol Metab 95:4600-8. 2010
    ..Children with Prader-Willi syndrome (PWS) are routinely treated with GH and have a response comparable with that observed in children with GH deficiency (GHD)...
  36. ncbi The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index
    Ginevra Corneli
    Division of Endocrinology and Metabolic Diseases, Department of Internal Medicine, University of Turin, Italy
    Eur J Endocrinol 153:257-64. 2005
    ..Aim of this study was to evaluate the diagnostic cut-off limits of peak GH response to the GHRH-ARG test in overweight and obese as well as in lean population...
  37. ncbi Evolution of IGF-1 in children born small for gestational age and with growth retardation, treated by growth hormone adapted to IGF-1 levels after 1 year
    S Cabrol
    Department of Paediatric Endocrinology, APHP, Hopital Armand Trousseau, Centre de Référence Maladies Endocriniennes Rares de la Croissance CRMERC and Research Unit 938 Inserm UPMC Paris VI, Paris, France
    Horm Res Paediatr 76:419-27. 2011
    ..This study was designed to estimate the percentage of growth hormone (GH)-treated children born small for gestational age (SGA), with serum IGF-1 >2 SDS before and after GH dose adaptation...
  38. pmc The effect of recombinant human growth hormone and resistance training on IGF-I mRNA expression in the muscles of elderly men
    M Hameed
    Department of Surgery, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK
    J Physiol 555:231-40. 2004
    ..The data suggest that when mechanical loading in the form of resistance training is combined with GH, MGF mRNA levels are enhanced. This may reflect an overall up-regulation of transcription of the IGF-I gene prior to splicing...
  39. ncbi Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences
    Martin Bidlingmaier
    Endocrine Research Laboratories, Medizinische Klinik Innenstadt, Ludwig Maximilians University, Munich, Germany
    Growth Horm IGF Res 20:19-25. 2010
    ..This review summarizes current practices for GH measurement with respect to the methods used, their limitations and the clinical consequences of the existing heterogeneity in GH immunoassay results...
  40. ncbi Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis
    Roger Abs
    Department of Endocrinology, University Hospital, Antwerp, Belgium
    Eur J Endocrinol 155:79-90. 2006
    ..The aim of the present study was to clarify the relationship between GH deficiency (GHD) and some cardiovascular risk factors and to analyse the effect of GH replacement therapy in a large number of patients over a prolonged period of time...
  41. ncbi Expression of functional recombinant human growth hormone in transgenic soybean seeds
    Nicolau B Cunha
    Embrapa Genetic Resources and Biotechnology, Parque Estação Biológica PqEB, Av W5 Norte, Brasilia, DF, 70770 917, Brazil
    Transgenic Res 20:811-26. 2011
    We produced human growth hormone (hGH), a protein that stimulates growth and cell reproduction, in genetically engineered soybean [Glycine max (L.) Merrill] seeds...
  42. ncbi Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly
    J J Kopchick
    Edison Biotechnology Institute, Department of Biomedical Sciences, College of Osteopathic Medicine, Ohio University, Athens, Ohio 45701, USA
    Endocr Rev 23:623-46. 2002
    ..This review charts the discovery and development of GHR antagonists and details the experience gained in patients with acromegaly...
  43. ncbi Body composition, IGF-I and IGFBP-3 concentrations as outcome measures in severely GH-deficient (GHD) patients after childhood GH treatment: a comparison with adult onset GHD patients
    Andrea F Attanasio
    Eli Lilly and Co, Florence 50019, Italy
    J Clin Endocrinol Metab 87:3368-72. 2002
    ..001 within each gender) were significantly lower in the CO group. These results suggest that patients with CO GHD who were treated to final height suffer a significant maturational deficit despite GH replacement during childhood...
  44. ncbi Body composition and quality of life in adults with growth hormone deficiency; effects of low-dose growth hormone replacement
    A M Ahmad
    Department of Diabetes and Endocrinology, Royal Liverpool University Hospital, Prescot Street, Liverpool, L7 8XP, UK
    Clin Endocrinol (Oxf) 54:709-17. 2001
    ..The aim of this study was to assess the effects of low-dose growth hormone replacement (GHR) on body composition and QoL as early as 1 and 3 months...
  45. ncbi Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency
    Beverly M K Biller
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Clin Endocrinol Metab 87:2067-79. 2002
    ..The ARG plus GHRH test represents an excellent alternative to the ITT for the diagnosis of GH deficiency in adults...
  46. ncbi Reduced insulin/IGF-1 signalling and human longevity
    Diana van Heemst
    Section of Gerontology and Geriatrics, Department of General Internal Medicine, Leiden University Medical Centre, PO Box 9600, 2300 RC Leiden, The Netherlands
    Aging Cell 4:79-85. 2005
    ..This effect was stronger for the GH1 SNP than for variation in the conserved IIS genes that were found to affect longevity in model organisms...
  47. ncbi Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children
    Bert Bakker
    Genentech, Inc, 1 DNA Way, mailstop 454 B, South San Francisco, California 94080, USA
    J Clin Endocrinol Metab 93:352-7. 2008
    ..Although GH has been used to treat short stature in GH deficiency (GHD) and other conditions for more than 40 yr, criteria for satisfactorily defining targets for GH responsiveness have never been developed...
  48. ncbi Divergent functions of neuronal Rab11b in Ca2+-regulated versus constitutive exocytosis
    Mikhail V Khvotchev
    Center for Basic Neuroscience, Department of Molecular Genetics, and Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9111, USA
    J Neurosci 23:10531-9. 2003
    Using PC12 cells that express transfected human growth hormone (hGH) as a secreted reporter protein, we have searched for Rab proteins that function in exocytosis...
  49. ncbi The effect of cessation of growth hormone (GH) therapy on bone mineral accretion in GH-deficient adolescents at the completion of linear growth
    W M Drake
    Department of Endocrinology, St Bartholomew s Hospital, London EC1A 7BE, United Kingdom
    J Clin Endocrinol Metab 88:1658-63. 2003
    ..This may predispose to clinically significant osteopenia in later adult life...
  50. ncbi The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults
    Linda J Woodhouse
    School of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada
    Endocr Rev 27:287-317. 2006
    ....
  51. ncbi The influence of gender on the short and long-term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: a 5-year study
    W M Drake
    Department of Endocrinology, St Bartholomew's Hospital, London UK
    Clin Endocrinol (Oxf) 54:525-32. 2001
    ..This constitutes a genuine gender difference in susceptibility given that serum IGF-I was in the upper part of the reference range in all subjects...
  52. ncbi Growth hormone and insulin-like growth factor I protect intestinal cells from radiation induced apoptosis
    P G Mylonas
    Division of Endocrinology, Department of Internal Medicine, University of Patras Medical School, 26500, Patras, Greece
    Mol Cell Endocrinol 160:115-22. 2000
    ..We have shown that abdominal radiation causes intestinal epithelial cell damage mainly through the induction of apoptosis and the treatment with GH and IGF-I inhibits apoptosis of the cells and preserves the mucosal integrity...
  53. ncbi Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency
    B M Biller
    Neuroendocrine Unit and General Clinical Research Center, Massachusetts General Hospital, and Harvard Medical School, Boston 02114, USA
    J Clin Endocrinol Metab 85:970-6. 2000
    ..Therefore, there is a critical differential response of the duration of GH action on different body composition compartments. Physiological GH administration has a persistent effect on bone mass 18 months after discontinuation of GH...
  54. ncbi Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease
    Maria Vittoria Davi'
    Clinic of Internal Medicine D, Department of Biomedical and Surgical Sciences, University of Verona, Policlinico GB Rossi, Verona, Italy
    Eur J Endocrinol 159:533-40. 2008
    ..Whether sleep apnoea syndrome (SAS) subsides after biochemical and clinical remission of acromegaly is controversial...
  55. ncbi The role of STAT proteins in growth hormone signaling
    J Herrington
    Department of Physiology, University of Michigan Medical School, Ann Arbor, Michigan, MI 48109 0622, USA
    Oncogene 19:2585-97. 2000
    ..Particular attention will be given to the novel role that STAT5 plays in sexually dimorphic gene expression in the liver as determined by the secretory pattern of GH and the role of STAT5 in body growth. Oncogene (2000)...
  56. ncbi Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial
    Yvonne van Pareren
    Department of Pediatrics, Division of Endocrinology, Sophia Children s Hospital Erasmus Medical Center, 3015 GJ Rotterdam, The Netherlands
    J Clin Endocrinol Metab 88:3584-90. 2003
    ..In conclusion, long-term continuous GH treatment in short children born SGA without signs of persistent catch-up growth leads to a normalization of AH, even with a GH dose of 3 IU/m(2).d ( approximately 0.033 mg/kg.d)...
  57. ncbi Growth hormone and bone
    C Ohlsson
    Research Centre for Endocrinology and Metabolism, Sahlgrenska University Hospital, Goteborg, Sweden
    Endocr Rev 19:55-79. 1998
    ..The advantage of GH-releasing factors over GH is that some of them can be administered orally and that they may induce a more physiological GH secretion. (ABSTRACT TRUNCATED)..
  58. ncbi Cost-utility of somatropin (rDNA origin) in the treatment of growth hormone deficiency in children
    Ashish V Joshi
    Novo Nordisk Inc, Princeton, NJ 08540, USA
    Curr Med Res Opin 22:351-7. 2006
    ..The objective of this study was to generate estimates of cost-effectiveness/utility of somatropin (rDNA origin) in the treatment of growth hormone deficiency (GHD) in children...
  59. ncbi Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H)
    Myriam Rosilio
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Indiana 46285, USA
    J Clin Endocrinol Metab 89:1684-93. 2004
    ..The authors suggest that evaluation of QoL should be a part of the routine clinical management of adult GH-deficient patients, complementing the measurement of surrogate biological markers or other clinical end points...
  60. ncbi Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study
    Pinchas Cohen
    Department of Pediatric Endocrinology, Mattel Children s Hospital at UCLA, 10833 Le Conte Avenue, MDCC 22 315, Los Angeles, California 90095, USA
    J Clin Endocrinol Metab 92:2480-6. 2007
    ..Weight-based dosing of GH is the standard of care for short children, although IGF-I is thought to be the main mediator of GH actions on growth...
  61. ncbi Ten years of growth hormone (GH) replacement normalizes muscle strength in GH-deficient adults
    Galina Götherström
    Research Centre for Endocrinology and Metabolism, Sahlgrenska University Hospital, Goteborg, Sweden
    J Clin Endocrinol Metab 94:809-16. 2009
    ..0 yr; range 22-74 yr) with adult-onset GH deficiency...
  62. ncbi The GH/IGF-I axis and pituitary function and size in adults with Prader-Willi syndrome
    I C van Nieuwpoort
    Section of Endocrinology, Department of Internal Medicine, VU University Medical Center and Neuroscience Campus Amsterdam, Amsterdam, The Netherlands ic vannieuwpoort vumc nl
    Horm Res Paediatr 75:403-11. 2011
    ..The aim of this study was to gain more insight into endocrine function in PWS adults, with emphasis on GH secretion...
  63. pmc Nanomedicines in the treatment of acromegaly: focus on pegvisomant
    Ferdinand Roelfsema
    Department of Endocrinology and Metabolism, Leiden University Medical Center, Leiden, The Netherlands
    Int J Nanomedicine 1:385-98. 2006
    ....
  64. pmc Complex signatures of locus-specific selective pressures and gene conversion on Human Growth Hormone/Chorionic Somatomammotropin genes
    Laura Sedman
    Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia
    Hum Mutat 29:1181-93. 2008
    ..The Human Growth Hormone/Chorionic Somatomammotropin (hGH/CSH) gene cluster (48 kb) at 17q22-24, consisting of one pituitary-..
  65. ncbi Long-term experience of pegvisomant therapy as a treatment for acromegaly
    C E Higham
    Department of Endocrinology, Christie Hospital, Manchester, UK
    Clin Endocrinol (Oxf) 71:86-91. 2009
    ..To evaluate the long-term efficacy and safety of pegvisomant as a treatment for acromegaly...
  66. ncbi Improved solubilization of recombinant human growth hormone inclusion body produced in Escherichia coli
    Hiroyuki Sonoda
    Medical Technology Research Center, Research Division, JCR Pharmaceuticals Co, Ltd, Kobe, Japan
    Biosci Biotechnol Biochem 72:2675-80. 2008
    Recombinant human growth hormone (r-hGH) overexpressed in Escherichia coli forms inactive and insoluble aggregates as inclusion bodies in the cytoplasm...
  67. ncbi Bone mineral density and effects of growth hormone treatment in prepubertal children with Prader-Willi syndrome: a randomized controlled trial
    Roderick F A de Lind van Wijngaarden
    Dutch Growth Research Foundation, Erasmus University Medical Center Sophia Children s Hospital, 3016 AH Rotterdam, The Netherlands
    J Clin Endocrinol Metab 94:3763-71. 2009
    ..Bone mineral density (BMD) is unknown in children with Prader-Willi syndrome (PWS), but is decreased in adults with PWS. In patients with GH deficiency, BMD increases during GH treatment...
  68. ncbi Growth hormone secretory pattern in non-obese children and adolescents with Prader-Willi syndrome
    Graziano Grugni
    Department of Auxology, S Giuseppe Hospital, Research Institute, Italian Auxological Institute Foundation, Verbania, Italy
    J Pediatr Endocrinol Metab 24:477-81. 2011
    ..0001). Subnormal IGF-I values were present in 19 PWS individuals (82.6%) and two healthy controls (6.2%). These findings are in agreement with the hypothesis that a complex derangement of hypothalamus-pituitary axis occurs in PWS...
  69. ncbi Prevalence and incidence of diabetes mellitus in adult patients on growth hormone replacement for growth hormone deficiency: a surveillance database analysis
    Andrea F Attanasio
    Cascina del Rosone, 14041 Agliano Terme, Italy
    J Clin Endocrinol Metab 96:2255-61. 2011
    ..GH replacement in adult GH-deficient patients may cause insulin resistance, raising concerns of potential increased risk of developing diabetes mellitus (DM)...
  70. ncbi ACROSTUDY: the first 5 years
    Peter J Trainer
    Department of Endocrinology, Christie Hospital, Manchester, UK
    Eur J Endocrinol 161:S19-24. 2009
    ..Further effort is needed to understand the reasons for the failure of dose titration...
  71. ncbi Surface plasmon resonance biosensor for direct detection of antibodies against human growth hormone
    Asta Kausaite-Minkstimiene
    Centre of Nanotechnology and Material science Nanotechnas, Faculty of Chemistry, Vilnius University, Naugarduko 24, LT 03225, Vilnius 6, Lithuania
    Analyst 134:2051-7. 2009
    A direct, label-free detection method of antibodies against the human growth hormone (anti-HGH) using a surface plasmon resonance (SPR) biosensor is reported...
  72. ncbi Prevalence and incidence of diabetes mellitus in GH-treated children and adolescents: analysis from the GeNeSIS observational research program
    Christopher J Child
    Lilly Research Laboratories, Erl Wood Manor, Windlesham GU20 6PH, United Kingdom
    J Clin Endocrinol Metab 96:E1025-34. 2011
    ..GH has an insulin antagonist effect, and GH treatment has therefore been suggested to impair glucose metabolism and increase risk of diabetes mellitus...
  73. ncbi Growth hormone secretion among adult patients with Prader-Willi syndrome due to different genetic subtypes
    G Grugni
    Division of Auxology, S Giuseppe Hospital, Research Institute, Istituto Auxologico Italiano, Verbania, Italy
    J Endocrinol Invest 34:493-7. 2011
    ..Few data are currently available on the relationship existing between endocrine abnormalities in PWS subjects and the different genotypes...
  74. ncbi Periplasmic expression of human growth hormone via plasmid vectors containing the lambdaPL promoter: use of HPLC for product quantification
    Carlos R J Soares
    Biotechnology Department, IPEN CNEN, Av Prof Lineu Prestes, 2242, Cidade Universitaria, 05508 900, Sao Paulo, Brazil
    Protein Eng 16:1131-8. 2003
    The influence of different factors acting on Escherichia coli periplasmic expression of recombinant human growth hormone (hGH) in shake flask cultures has been investigated...
  75. ncbi Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy
    Monica Marazuela
    Hospital Universitario de la Princesa, Universidad Autonoma de Madrid, Spain
    Eur J Endocrinol 160:535-42. 2009
    ..Pegvisomant is an effective treatment for somatostatin analogue-resistant acromegaly, but the determinants defining the response to this treatment are largely unknown...
  76. ncbi Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency
    G S Conway
    Department of Endocrinology and Diabetes, University College London Hospitals, 250 Euston Road, London NW1 2PQ, UK
    Eur J Endocrinol 160:899-907. 2009
    ..In the present study, we analyzed the impact of GH treatment on bone in young adults with GHD...
  77. ncbi Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant
    S J C M M Neggers
    Department of Internal Medicine, Erasmus University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands
    J Clin Endocrinol Metab 93:3853-9. 2008
    ....
  78. ncbi Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy in comparison with fixed body weight-based dosing
    Andrew R Hoffman
    Medical Service, Veterans Affairs Palo Alto Health Care System and Stanford University, 3801 Miranda Avenue, Palo Alto, CA 94304, USA
    J Clin Endocrinol Metab 89:3224-33. 2004
    ..We conclude that GH replacement therapy should be initiated at a low dose and titrated to a dose producing maximal benefits without adverse side effects and an IGF-I level within the age- and sex-adjusted normal range...
  79. ncbi Comparative results of a 4-year study on cardiovascular parameters, lipid metabolism, body composition and bone mass between untreated and treated adult growth hormone deficient patients
    H L Fideleff
    Endocrinology Unit Department of Medicine, Hospital T Alvarez, Aranguren 2701 C1406FWY, Buenos Aires, Argentina
    Growth Horm IGF Res 18:318-24. 2008
    ....
  80. ncbi Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome
    Dederieke A M Festen
    Dutch Growth and Research Foundation, Rotterdam, The Netherlands
    Clin Endocrinol (Oxf) 69:443-51. 2008
    ..Prader-Willi syndrome (PWS) children have impaired growth, and abnormal body composition. Previous 1-year controlled studies showed improvement of height and body composition during GH-treatment...
  81. pmc Over- and underdosage of SOX3 is associated with infundibular hypoplasia and hypopituitarism
    Kathryn S Woods
    London Centre for Paediatric Endocrinology, Biochemistry, Endocrinology, and Metabolism Unit, Institute of Child Health, University College London, London, United Kingdom
    Am J Hum Genet 76:833-49. 2005
    ..We conclude that both over- and underdosage of SOX3 are associated with similar phenotypes, consisting of infundibular hypoplasia and hypopituitarism but not necessarily MR...
  82. ncbi Effect of growth hormone therapy and puberty on bone and body composition in children with idiopathic short stature and growth hormone deficiency
    Wolfgang Hogler
    Institute of Endocrinology and Diabetes, The Children s Hospital at Westmead, Locked Bag 4001, NSW 2145, Sydney, Australia
    Bone 37:642-50. 2005
    ..Growth hormone had great effects on the growth plate and body composition with subsequent gains in height, LTM, bone turnover, and bone mass accrual, but no benefit for volumetric bone density over 2 years...
  83. ncbi Sarcopenia of aging and its metabolic impact
    Helen Karakelides
    Division of Endocrinology and Metabolism, Mayo Clinic, Rochester, Minnesota 55905, USA
    Curr Top Dev Biol 68:123-48. 2005
    ..The way in which age-related changes in hormone levels affect muscle remains to be fully understood. The effect of replacing those hormones on sarcopenia has led to some conflicting results, but further investigations are ongoing...
  84. ncbi Expression of human growth hormone in transgenic rice cell suspension culture
    Tae Geum Kim
    Division of Biological Sciences and the Research Center for Bioactive Materials, Chonbuk National University, Jeonju 561 756, South Korea
    Plant Cell Rep 27:885-91. 2008
    b>Human growth hormone (hGH), a pituitary-derived polypeptide, evidences a wide range of biological functions, including protein synthesis, cell proliferation, and metabolism...
  85. pmc Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency
    Mariam Elbornsson
    Department of Endocrinology, Institute of Medicine, Sahlgrenska Academy, Sahlgrenska University Hospital, University of Gothenburg, Grona Straket 8, SE 413 45 Goteborg, Sweden
    Eur J Endocrinol 166:787-95. 2012
    ..Few studies have determined the effects of more than 5-10 years of GH replacement in adults on bone mineral content (BMC) and bone mineral density (BMD)...
  86. ncbi Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient children
    S F Kemp
    University of Arkansas for Medical Sciences at Arkansas Children s Hospital, 800 Marshall Street, Springer Building, Little Rock, AR 72202, USA
    J Clin Endocrinol Metab 89:3234-40. 2004
    ..Nutropin Depot administration once or twice per month provides serum levels of GH and IGF-I expected to promote growth, without accumulation of GH, IGF-I, or IGF binding protein-3, in children with GHD...
  87. ncbi Prevalence of the metabolic syndrome in moderately-severely obese subjects with and without growth hormone deficiency
    C Di Somma
    IRCCS SDN Foundation, Naples, Italy
    J Endocrinol Invest 33:171-7. 2010
    ....
  88. ncbi Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency
    Yutaka Takahashi
    Division of Endocrinology Metabolism, Neurology, and Hematology Oncology, Department of Clinical Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
    Gastroenterology 132:938-43. 2007
    ..Moreover, liver dysfunctions with hyperlipidemia and nonalcoholic fatty liver disease (NAFLD) are frequently observed in patients with AGHD, and it is accompanied by metabolic syndrome...
  89. ncbi The German ACROSTUDY: past and present
    M Buchfelder
    Department of Neurosurgery, University of Erlangen Nurnberg, Germany
    Eur J Endocrinol 161:S3-S10. 2009
    ..The German data are now merged into the global ACROSTUDY and will constitute a major portion of the international ACROSTUDY project as a continuing global web-based observational study...
  90. ncbi Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: a retrospective, comparative, head-to-head study
    R S Auriemma
    Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, University Federico II of Naples, 80131 Naples, Italy
    J Endocrinol Invest 31:956-65. 2008
    ..Therefore, both drugs can be safely employed as first-line therapy of acromegaly...
  91. ncbi Bone mineral density and body composition in adolescents with childhood-onset growth hormone deficiency
    Annemieke M Boot
    Department of Pediatrics, Division of Pediatric Endocrinology, University Medical Center Groningen, The Netherlands
    Horm Res 71:364-71. 2009
    ..The aim of the present study was to evaluate bone mineral density (BMD) and body composition of patients with childhood-onset growth hormone (GH) deficiency (GHD) treated with GH during the transition period...
  92. ncbi Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency
    Kevin C J Yuen
    Department of Endocrinology and Paediatrics, Addenbrooke s Hospital, Cambridge, UK
    Clin Endocrinol (Oxf) 63:428-36. 2005
    ....
  93. ncbi Favorable long-term effects of growth hormone replacement therapy on quality of life, bone metabolism, body composition and lipid levels in patients with adult-onset growth hormone deficiency
    A P Jørgensen
    Section of Endocrinology, Oslo University Hospital, Faculty of Medicine, University of Oslo, Norway
    Growth Horm IGF Res 21:69-75. 2011
    ....
  94. ncbi Biodegradable polymeric microspheres with "open/closed" pores for sustained release of human growth hormone
    Hong Kee Kim
    Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, 305 701, Republic of Korea
    J Control Release 112:167-74. 2006
    ..Recombinant human growth hormone (rhGH) was incorporated into porous microspheres by a simple solution dipping method...
  95. ncbi Fracture incidence in GH-deficient patients on complete hormone replacement including GH
    Helene Holmer
    Department of Internal Medicine, Centralsjukhuset, Kristianstad, Sweden
    J Bone Miner Res 22:1842-50. 2007
    ..Studying fracture incidence in 832 patients on GH therapy and 2581 matched population controls, we recorded a doubled fracture risk in CO GHD women, but a significantly lower fracture risk in AO GHD men...
  96. ncbi Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly
    Peiming Ma
    Novartis Pharma KK, Tokyo 106 8618, Japan
    Clin Pharmacol Ther 78:69-80. 2005
    ..SOM230, a novel somatostatin analog, was compared with octreotide with respect to pharmacokinetic (PK) profiles and inhibition of GH secretion in acromegalic patients...
  97. ncbi Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients
    S J C M M Neggers
    Department of Medicine, Erasmus University, Erasmus MC, Rotterdam, The Netherlands
    Eur J Endocrinol 160:529-33. 2009
    ..We previously reported on the efficacy, safety, and quality of life (QoL) of long-acting somatostatin analogs (SSA) and (twice) weekly pegvisomant (PEG-V) in acromegaly and improvement after the addition of PEG-V to long-acting SSA...
  98. ncbi Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics
    Jean De Schepper
    UZ Brussel, Department of Pediatrics Laarbeeklaan 101, 1090 Brussels, Belgium
    Eur J Endocrinol 165:401-9. 2011
    ..This study determined the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating single doses of a pegylated GH (NNC126-0083) developed for once-weekly administration, in children with GH deficiency (GHD)...
  99. ncbi Cardiovascular risk factors in hypopituitary GH-deficient adults
    Johan Verhelst
    Department of Endocrinology, ZNA Middelheim, Antwerp, Belgium
    Eur J Endocrinol 161:S41-9. 2009
    ..No subgroup yet has been identified as not responding well to GH...
  100. ncbi Monitoring of concordance in growth hormone therapy
    R R Kapoor
    Department of Paediatrics, Addenbrooke s Hospital, University of Cambridge, Cambridge, UK
    Arch Dis Child 93:147-8. 2008
    ..Lower concordance was associated with longer duration on GH therapy (p<0.005), lack of choice of delivery device (p<0.005) and short prescription durations (p<0.005), and predicted lower height velocities (p<0.05)...
  101. ncbi Cancers associated with acromegaly
    Paul J Jenkins
    Department of Endocrinology, St Bartholomew s Hospital, London, UK
    Neuroendocrinology 83:218-23. 2006
    ..However, these associations have been based mostly on small epidemiological surveys and circumstantial evidence. Large-scale epidemiological studies are required to clarify this issue...

Research Grants62

  1. Transferrin Conjugates for Oral Protein Drug Delivery
    Wei Chiang Shen; Fiscal Year: 2013
    ..e., granulocyte colony-stimulating factor (G-CSF), human growth hormone (hGH) and proinsulin (ProINS)...
  2. CONTROLLED RELEASE OF MACROMOLECULES
    ROBERT SAMUEL LANGER; Fiscal Year: 2013
    ..Therefore, we propose to develop combinatorial libraries of new materials with the specific goal of generating clinically useful, non-viral methods for gene therapy. ..
  3. Natural history of bone disease and the impact of growth hormone treatment in MPS
    LYNDA ELIZABETH POLGREEN; Fiscal Year: 2013
    ..Polgreen will pursue the following specific aims: 1) To determine the impact of 24 months of recombinant human growth hormone therapy versus no therapy on bone development and growth in 34 children with MPS I, II, and VI and short ..
  4. LCR ACTIVATION OF THE HUMAN GROWTH HORMONE GENE
    STEPHEN AARON LIEBHABER; Fiscal Year: 2013
    A distal locus control region (LCR) regulates the human growth hormone (hGH) gene cluster. Four DNaseI hypersensitive sites, HSI, II, III, and V located between 14...
  5. Improving Protein Delivery and Circulation via FcRn Ligands
    Francis C Szoka; Fiscal Year: 2013
    ..Aim 3. Evaluate the therapeutic potential of FcRn binding peptide-modified human growth hormone (hGH) in a murine model of growth hormone deficiency...
  6. Activation of Human Placental Hormonal Expression
    STEPHEN AARON LIEBHABER; Fiscal Year: 2013
    ..Both hormones are encoded in the multi-gene human growth hormone (hGH) gene cluster that also encompasses the pituitary growth hormone gene, hGH-N...
  7. REGULATION OF SKELETAL GROWTH IN RENAL FAILURE
    CHERYL SANCHEZ; Fiscal Year: 2003
    ..Calcitriol and recombinant human growth hormone are widely utilized to improve liner growth in children, but large intermittent doses of calcitriol have ..
  8. Exploring Cytokine-Induced Receptor Activation Using a Novel Semi-Synthetic Mode
    SHAHIR RIZK; Fiscal Year: 2010
    ..proteins and synthetic peptides providing a novel platform for biophysical characterization of the human growth hormone receptor. The components will be assembled by native chemical ligation to restore native peptide bonds...
  9. Mechanisms &Energetics of Transmembrane-induced Signaling of Cytokine Receptors
    Wonpil Im; Fiscal Year: 2013
    ..In this proposal, we will use human growth hormone receptor (hGHR) and human prolactin receptor (hPRLR) as prototypical model systems for homodimeric TM-..
  10. Positron Emission Tomography to Evaluate Thymic Function
    Laura Napolitano; Fiscal Year: 2006
    ..a prospective study of 5 immunodeficient adults with HIV-1 infection, we found that the administration of human growth hormone was associated with reversal of thymic involution and an increase in circulating naive CD4+ T cells...
  11. MECHANISMS IN THE REGULATION OF SP-A GENE EXPRESSION
    CAROLE MENDELSON; Fiscal Year: 2007
    ..In studies using transgenic mice[unreadable] carrying SP-A:human growth hormone (hGH) reporter genes, we have found[unreadable] that as little as 400 bp of SP-A 5'-flanking sequence ..
  12. ENDOCHONDRAL BONE FORMATION IN RENAL FAILURE
    ISIDRO SALUSKY; Fiscal Year: 1999
    ..Calcitriol and recombinant human growth hormone (rhGH) are widely utilized to improve linear growth in these children...
  13. Creutzfeldt-Jakob Disease Surveillance in Recipients of Human Growth Hormone
    Russell Walker; Fiscal Year: 2011
    The NIDDK Creutzfeldt-Jakob Disease Surveillance in Recipients of Human Growth Hormone project is overseen by the Interagency Committee on Human Growth Hormone (hGH) and Creutzveldt-Jakob Disease (CJD) and includes representives from ..
  14. Creutzfeldt-Jakob Disease Surveillance in Recipients of Human Growth Hormone
    Russell Walker; Fiscal Year: 2009
    The NIDDK Creutzfeldt-Jakob Disease Surveillance in Recipients of Human Growth Hormone project is overseen by the Interagency Committee on Human Growth Hormone (hGH) and Creutzveldt-Jakob Disease (CJD) and includes representives from ..
  15. Creutzfeldt-Jakob Disease Surveillance in Recipients of Human Growth Hormone
    Russell Walker; Fiscal Year: 2012
    The NIDDK Creutzfeldt-Jakob Disease Surveillance in Recipients of Human Growth Hormone project is overseen by the Interagency Committee on Human Growth Hormone (hGH) and Creutzveldt-Jakob Disease (CJD) and includes representives from ..
  16. IGF::OT::IGF CREUTZFELDT-JAKOB DISEASE SURVEILLANCE IN RECIPIENTS OF HUMAN GROWT
    Steve Durako; Fiscal Year: 2013
    The NIDDK Creutzfeldt-Jakob Disease Surveillance in Recipients of Human Growth Hormone project is overseen by the Interagency Committee on Human Growth Hormone (hGH) and Creutzveldt-Jakob Disease (CJD) and includes representives from ..
  17. Creutzfeldt-Jakob Disease Surveillance in Recipients of Human Growth Hormone
    Russell Walker; Fiscal Year: 2010
    The NIDDK Creutzfeldt-Jakob Disease Surveillance in Recipients of Human Growth Hormone project is overseen by the Interagency Committee on Human Growth Hormone (hGH) and Creutzveldt-Jakob Disease (CJD) and includes representives from ..
  18. AMINO ACID TRANSPORT AFTER SMALL BOWEL RESECTION
    HARRY SAX; Fiscal Year: 2004
    ..The parenteral administration of epidermal growth factor (EGF) and/or human growth hormone (GH) increases sodium-dependent glutamine transport after 70% enterectomy in rabbits...
  19. Glycine rich sequences with pharmacokinetic enhancing properties of PEG polymers
    Volker Schellenberger; Fiscal Year: 2009
    ..Our phase II goal is to apply rPEG technology to human growth hormone (hGH). hGH is currently used for the treatment of dwarfism in children. 2006 sales exceeded $3B...
  20. CABP GENE INTERACTION WITH VITAMIN D3 RECEPTOR
    Barry Komm; Fiscal Year: 1991
    ..into plasmid vectors containing reporter genes such as chloramphenicol acetyl transferase (CAT) or human growth hormone (hGH) and transfected into cell lines that express the 1,25 (OH)2 D3 receptor (ROS 17.2...
  21. Physiologic Role of the Somatotroph IGF-1 Receptor
    Christopher Romero; Fiscal Year: 2009
    ..neuroendocrine role of IGF-1 feedback using provocative testing for the release of hypothalamic factors, human growth hormone releasing hormone (GHRH) and somatostatin...
  22. PROTEINS OF PHYSIOLOGICAL INTEREST: STRUCTURE-FUNCTION
    John Moffat; Fiscal Year: 1990
    ..Such a structure will yield a trial model for the related growth hormones and prolactins. One of these, human growth hormone, is of considerable clinical importance, and another, bovine growth hormone, is becoming of agronomic ..
  23. THE ROLE OF PROLACTIN IN HUMAN BREAST CANCER
    David Kleinberg; Fiscal Year: 1980
    ..This year we extended our observations and found that human growth hormone is a more potent lactogen than ovine prolactin in these subhuman primate mammary tissues...
  24. INJECTABLE CALCIUM SULFATE MICROSPHERES FOR PROTEINS
    Larry Nichols; Fiscal Year: 2000
    ..will use the data from Phase I to develop an injectable microsphere depot for a medicinal protein such as human growth hormone and will then pursue product development through demonstration of reproducibility, prototype manufacturing, ..
  25. TRANSCRIPTIONAL CONTROL OF SERUM AMYLOID GENES
    Hugh Rienhoff; Fiscal Year: 1991
    ..The putative promoters will be fused to the human growth hormone structural gene and introduced into fertilized mouse ova; transgenic studies may help to identify tissue-..
  26. ETIOLOGY OF GROWTH FAILURE IN BILIARY ATRESIA
    Barbara Haber; Fiscal Year: 2002
    ..2. Treatment of children with biliary atresia with either recombinant human growth hormone (rhGH) or supplemental nutrition early in the course of the liver disease will correct the alterations of ..
  27. MENTORED MEDICAL STUDENT CLINICAL RESEARCH PROGRAM
    David Herndon; Fiscal Year: 2000
    Preliminary data from a multicenter trial using recombinant human growth hormone (rhGH) in the treatment of children with severe thermal injury suggests that accelerated wound healing and improved protein metabolism occurs with this ..
  28. Novel Active Repressor Model of Human LDL-Receptor Regulation
    Johannes Veldhuis; Fiscal Year: 2008
    ..This would represent a new treatment approach for patients with atherosclerotic disease. [unreadable] [unreadable] [unreadable] [unreadable]..
  29. Ensemble Disruption of the GnRH-LH-Testosterone Axis
    Johannes Veldhuis; Fiscal Year: 2007
    ..Expected corollary outcomes are enhanced diagnosis, assessment and management of more subtle pathophysiology of the male gonadal axis in puberty and adulthood. ..
  30. Mechanistic bases for age-related androgen deficiency
    Johannes Veldhuis; Fiscal Year: 2007
    ..Knowing why testosterone falls should help foster new and safer ways to prevent the problem. [unreadable] [unreadable] [unreadable]..
  31. Analytical Reconstruction of Feedback Signaling in Aging Men
    Johannes Veldhuis; Fiscal Year: 2008
    ..The present proposal develops a general biomathematical framework for dissecting otherwise observed pathways that control hormone output in aging, stress and disease. [unreadable] [unreadable] [unreadable]..
  32. ACTIONS OF ESTROGEN IN MATURING GRAAFIAN FOLLICLES
    Johannes Veldhuis; Fiscal Year: 2005
    ..Understanding such fundamental interactions is important to the rational design of alternative strategies to interrupt normal and rescue impaired steroidogenesis in the maturing Graafian follicle and corpus luteum. ..
  33. THE AGING GH AXIS IN POSTMENOPAUSAL WOMEN
    Johannes Veldhuis; Fiscal Year: 2005
    ..An enhanced knowledge base should aid ultimately in formulating more innovative preventive and interventional strategies to limit hyposomatotropism in older and/or estrogen-deficient humans. ..
  34. ENSEMBLE MODEL OF STRESS ACTH-ADRENAL AXIS
    Johannes Veldhuis; Fiscal Year: 2005
    ....
  35. REGULATION OF TISSUE-SPECIFIC GENE EXPRESSION
    Elmus Beale; Fiscal Year: 1992
    ..transformation of cultured cells (transient assays) and transgenic mice using in vitro mutagenized PEPCK/human growth hormone chimeric genes...
  36. PEPTIDE DEGRADATION IN POLYMER MATRICES
    Elizabeth Topp; Fiscal Year: 2001
    Peptide and polypeptide drugs such as interferons, immunoconjugates, tissue plasminogen activator, human growth hormone and erythropoeitin, made available by the biotechnological revolution, are now entering the marketplace and presenting ..
  37. NEW BIODEGRADABLE POLYMERS FOR PROTEIN DRUG DELIVERY
    Sung Wan Kim; Fiscal Year: 1999
    ..The protein drugs, leuprorelin, human growth hormone (hGH) and bone morphogenic protein (BNV-2) will be loaded in the polymer microspheres...
  38. ANABOLIC HORMONES IN NUTRITION SUPPORT
    Thomas Ziegler; Fiscal Year: 1999
    ..factor mechanisms and interactions; 2) results and current status of clinical investigations on the role of human growth hormone, IGF-I, and anabolic steroids in catabolic states such as burns, trauma, critical illness, AIDS, and in the ..
  39. Insulin-like Growth Factor Receptor Antagonists
    DANIEL MONTICELLO; Fiscal Year: 2007
    ..Negative Ligand approach was clinically validated with the approval of Somavert, an engineered form of human growth hormone used to treat acromegaly...
  40. Casein Coated CAP Particles for Oral Insulin Delivery
    Tulin Morcol; Fiscal Year: 2003
    ..and adaptation of the delivery system to another orally challenged therapeutic protein, such as human growth hormone, would demonstrate general utility of the delivery system...
  41. MITIGATION OF EPISODIC WASTING IN HIV INFECTION
    Morris Schambelan; Fiscal Year: 2000
    ..Nutritional interventions can increase weight but fail to consistently restore LBM. Recombinant human growth hormone (rhGH) increased weight and LBM in stable patients and limited loss of LBM during weight-losing episodes, ..
  42. CYTOKINE AND HORMONE INTERACTIONS IN COMORBIDITY OF AIDS
    Keith Kelley; Fiscal Year: 2005
    ..AIDS patients with wasting are often given a 12- week therapy with very high doses of recombinant human growth hormone to increase plasma IGF-I, lean muscle mass and quality of life...
  43. DEVELOPMENTAL REGULATION OF FETAL ANTIOXIDANT EXPRESSION
    Jonathan Gitlin; Fiscal Year: 2001
    ..Finally we will generate transgenic mice using characterized upstream regions of the ceruloplasmin gene and human growth hormone and E. Coli lacZ reporter genes...
  44. PEPTIDE DEGRADATION IN POLYMER MATRICES
    Elizabeth Topp; Fiscal Year: 2003
    Peptide and polypeptide drugs such as interferons, immunoconjugates, tissue plasminogen activator, human growth hormone and erythropoeitin, made available by the biotechnological revolution, are now entering the marketplace and presenting ..
  45. DEVELOPMENT OF GROWTH HORMONE RELEASING FACTOR AGONISTS
    John Haley; Fiscal Year: 1991
    DESCRIPTION: (Adapted from Applicant's Abstract) Human growth hormone (hGH) is a major regulator of growth and metabolism. Recombinant hGH has been used to correct pituitary dwarfism...
  46. Disulfide Bond Formation: Mechanisms for Isomerization and Novel Pathways
    Jonathan Beckwith; Fiscal Year: 2009
    ..Medically important proteins- e.g. insulin, human growth hormone and antibodies- contain disulfide bonds essential for their activity...
  47. Human Heme Oxygenase-1 Gene Regulation by Oxidized LDL
    Anupam Agarwal; Fiscal Year: 2006
    ..Aim IIB will involve studies to characterize the oxLDL-responsive element using luciferase and human growth hormone reporter genes...
  48. GROWTH FACTOR CONJUGATES FOR TREATING HORMONAL DISEASES
    George Cox; Fiscal Year: 2001
    ..PROPOSED COMMERCIAL APPLICATION: Recombinant human Growth Hormone, G-CSF and EPO are used to treat short stature, cachexia, neutropenia and anemia and had world-wide sales ..
  49. Transgenic Goats Produced by Germ Cell Transplantation
    Ina Dobrinski; Fiscal Year: 2006
    ..The goats will carry the gene for human growth hormone (rhGH) under the control of a mammary gland specific promoter such that the milk of transgenic females will ..
  50. FRET METHOD FOR IDENTIFYING HORMONE ANTAGONISTS
    James Wells; Fiscal Year: 1999
    ..In Phase I of this project, FRET will be used in a primary assay to screen compounds for binding to human growth hormone (hGH)...
  51. HORMONAL CONTROL OF LENS GROWTH
    HOWARD ROTHSTEIN; Fiscal Year: 1980
    ..of hypophysectomized animals and hypophysectomized animals that have received replacement therapy with human growth hormone. The serological changes that occur in such organisms will also be documented...
  52. RAPID SCREENING OF HUMAN GROWTH HORMONE
    ROBERTA SULK; Fiscal Year: 2001
    ..to develop two prototype analyzers interfaced with automated microwell plate readers for rapid screening of human growth hormone (hGH) by Surface Enhanced Raman ImmunoAssay (SERIA)...
  53. CALCIUM BINDING PROTEINS: STRUCTURE AND FUNCTION
    John Moffat; Fiscal Year: 1980
    ..and to attempt crystallization of the purified form; to purify, further the already quite pure samples of human growth hormone and bovine prolactin and to attempt their crystallization...
  54. TRANSGENIC MODELS OF AUTOIMMUNE GASTRITIS
    ROBINNA LORENZ; Fiscal Year: 2001
    ..This model utilizes transgenic mice which express human growth hormone (hGH) exclusively in a subset of the gastric parietal cell population of the stomach and are functionally ..
  55. Detection of Prion Protein in Blood
    JIUPING JI; Fiscal Year: 2002
    ..I-PCR assay for Prion will also prevent well-documented cases of iatrogenic transmission through the use of human growth hormone, dura mater, organ transplantation, and the likelihood of transmission through the use of surgical ..
  56. PIT-1 ACTIVATION OF THE GROWTH HORMONE CHROMATIN LOCUS
    BRIAN SHEWCHUK; Fiscal Year: 2004
    ..The experiments that are proposed focus on activation of the human Growth Hormone (hGH) chromatin locus...
  57. MIMICS OF HELIX TURN HELIX PEPTIDES
    FELICIA ETZKORN; Fiscal Year: 2001
    ..POU homeodomains are transcription factors for human growth hormone, histones, snRNAs, immunoglobulin, herpes simplex virus and other medically important genes...
  58. NOVEL VERTEBRATE PROTEIN PRODUCTION--HIV
    David Kabat; Fiscal Year: 1991
    ..an approach that can solve this problem, and we have thereby isolated cell lines that produce secretory human growth hormone (hGH) as 4% of total protein (c.a., 6 mg/liter - 24h)...
  59. EPITHELIAL DIFFERENTIATION AND INTESTINAL SECRETION
    MARIAN NEUTRA; Fiscal Year: 1993
    ..18-N2 goblet cells transfected with foreign genes to sort and package a regulated endocrine cell product (human growth hormone) and a non-regulated plasma cell product (immunoglobulin light chain) will be analyzed before and after ..
  60. Solvent exchange methods for protein microencapsulation
    Kinam Park; Fiscal Year: 2006
    ..and preservation of protein drugs; (4) to prepare microcapsules loaded with protein drugs, such as human growth hormone and erythropoietin, and examine the stability of the loaded drugs, their release kinetics, and their long-..
  61. HUMAN GROWTH HORMONE PRODUCED IN TRANSGENIC RABBIT MILK
    Benjamin Snyder; Fiscal Year: 1992
    b>Human growth hormone (hGH) is an important therapeutic being produced at high cost by recombinant methods. The Phase I of this SBIR has demonstrated the feasibility of producing this hormone in the milk of transgenic mice...
  62. RAPID SCREENING OF HUMAN GROWTH HORMONE
    ROBERTA SULK; Fiscal Year: 1999
    The research described in this proposal details a procedure for detecting and quantifying Human Growth Hormone (HGH) using an immunoassay coupled with surface enhanced Raman scattering (SERS) spectroscopy...